Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases

Last month, As­cid­i­an Ther­a­peu­tics pre­sent­ed the first da­ta sug­gest­ing a new way to fix bro­ken genes may be safe in peo­ple. Now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.